Search Results - varghese+john

15 Results

Sort By:

Synthetic Exosomes (SE) for CNS Delivery of CRISPR for Gene Editing in Brain Disorders (UCLA Case No. 2021-363)

UCLA researchers from the Department of Neurology have developed synthetic exosomes, a novel delivery technology capable of transporting gene-editing tools and therapeutics across the blood-brain barrier, with successful applications in repairing Alzheimer’s-related mutations and delivering proteins, antibodies, and drugs. BACKGROUND: The emergence...

Published: 2/18/2025 | Inventor(s): Varghese John

Keywords(s): Alzheimers disease, CRISPR, delivery system, exosome, Nanotechnology, nanovesicles, synthetic biology

Category(s): Life Science Research Tools > Microfluidics And Mems, Materials > Nanotechnology, Platforms > Drug Delivery, Therapeutics > Gene Therapy And Editing, Therapeutics > CNS and Neurology

Salivary Exosome (NSEV) Analysis to Elucidate Intercellular Signaling Events that Precede Pilot Fatigue (UCLA Case No. 2021-172)

Researchers at UCLA’s Department of Neurology and Drug Discovery Lab have identified a novel set of biomarkers that change based on levels of Cognitive Fatigue (CF). These biomarkers can be used to non-invasively predict and assess levels of cognitive fatigue. BACKGROUND: Cognitive fatigue (CF) is an important factor in the efficiency and safety...

Published: 2/14/2025 | Inventor(s): Bruce Teter, Whitaker Cohn, Varghese John

Keywords(s): biomarkers, cognitive fatigue, exosome, noninvasive, non-invasive

Category(s): Diagnostic Markers > Targets And Assays

Small Molecule Humanin Mimetics and Enhancers That Normalize Neuronal p-AKT as Novel Therapeutics for Alzheimer's Disease (UCLA Case No. 2023-230)

UCLA researchers in the Department of Neurology have discovered novel small molecule humanin mimetics for the treatment of Alzheimer's disease and other chronic conditions with dysregulated p-Akt. BACKGROUND: Alzheimer’s disease (AD) is the most common form of dementia accounting for 60-70% of all cases. Nearly 7 million Americans are living...

Published: 2/14/2025 | Inventor(s): Varghese John

Keywords(s): Alzheimers disease, Cardiovascular, Cardiovascular Disease, Dementia, diabetes, mimetics, pAKT signaling, small molecules

Category(s): Therapeutics > CNS and Neurology, Therapeutics > Cardiovascular

2021-241: Enhancers of Brain Gamma Oscillations for Treatment of Neurological Disorders

SUMMARY: UCLA researchers in the Department of Neurology have developed a novel small molecule to improve native gamma oscillations as a treatment for cognitive decline in various neurological disorders. BACKGROUND: Neural circuits are facilitated by brain oscillations or rhythmic electric activity at distinct frequencies. These frequency variations...

Published: 2/14/2025 | Inventor(s): Varghese John, Istvan Mody, Jesus Campagna, Barbara Jagodzinska, Xiaofei Wei

Keywords(s):

Category(s): Therapeutics > CNS and Neurology, Therapeutics > Psychiatry And Mental Health

2022-177: DRUG COMBINATION TO INHIBIT BOTH MPRO AND PLPRO PROTEASES OF SARS-COV-2

SUMMARY: UCLA researchers in the Department of Neurology have developed a novel small-molecule protease inhibitor cocktail to robustly suppress COVID-19 infection. INTRODUCTION: COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. Despite the development of vaccines, COVID-19 was the third-leading cause of death in the U.S. in 2021,...

Published: 2/14/2025 | Inventor(s): Varghese John, Robert Damoiseaux, Man Hing Li

Keywords(s):

Category(s): Therapeutics, Therapeutics > Infectious Diseases, Therapeutics > Infectious Diseases > COVID

2020-832: Novel Compounds Targeting APOE4 That Enhance Brain SIRT1 Levels and Target Novel Mechanism of Action

Researchers at UCLA's Drug Discovery Lab and Department of Chemistry have developed new chemical entity (NCE) analogs of A03, which together form a new class of compounds that target apolipoprotein E4 (ApoE4)-mediated deficits in the tau deacetylase enzyme, sirtuin 1 (SirT1). These NCEs provide an opportunity for novel therapeutic development in Alzheimer's...

Published: 2/14/2025 | Inventor(s): Varghese John, Jesus Campagna, Michael Jung

Keywords(s): Brain

Category(s): Therapeutics

2020-408: sAPPalpha Targeted Therapeutics for Alzheimer’s Disease

UCLA researchers from the Department of Neurology have developed a novel application of two compounds that target the upstream formation of toxic amyloid-beta oligomers for the effective treatment of Alzheimer’s disease. BACKGROUND: Alzheimer’s Disease (AD) is the most common age-related neurodegenerative disorder currently affecting ~6...

Published: 2/14/2025 | Inventor(s): Varghese John, Sujyoti Chandra

Keywords(s): Chemical, Cns, Therapeutics & Vaccines

Category(s): Therapeutics, Therapeutics > CNS and Neurology

2018-200 AMYLOID PRECURSOR PROTEIN-SELECTIVE BACE INHIBITORS (ASBIS) FOR ALZHEIMER’S DISEASE

Amyloid Precursor Protein-Selective BACE Inhibitors for Alzheimer’s DiseaseSUMMARYUCLA researchers in the Department of Neurology have invented novel Alzheimer’s disease (AD) therapeutics that are selective for BACE1 inhibition and cleavage of the amyloid precursor protein (APP) substrate.BACKGROUNDAlzheimer’s disease is characterized...

Published: 2/14/2025 | Inventor(s): Barbara Jagodzinska, Varghese John, Patricia Spilman, Jesus Campagna

Keywords(s): Cns, Life Science Research Tools, Medical Devices and Materials, Targets And Assays, Therapeutics & Vaccines

Category(s): Life Science Research Tools, Diagnostic Markers > Targets And Assays, Medical Devices, Therapeutics, Therapeutics > CNS and Neurology

2019-231: Radiotracer for Synaptic Imaging

UCLA researchers in the Department of Neurology have synthesized a novel radiotracer that selectively identifies functional synapses for monitoring of synaptic loss in Alzheimer’s patients. BACKGROUND: Alzheimer’s disease (AD) is a debilitating neurodegenerative disorder that cannot be prevented, cured or slowed. It affects more than 17...

Published: 2/14/2025 | Inventor(s): Varghese John, Mohammad Parvez Alam, Asa Hatami, Daniel Silverman, Seyed Saman Sadeghi Hosseini

Keywords(s): Cns, Diagnostic Markers & Platforms, Medical Imaging, PET

Category(s): Medical Devices > Medical Imaging > PET

Identification and Development of Dual nSMase2-AChE Inhibitors for Neurodegenerative Disorders (UCLA Case No. 2019-279)

UCLA researchers in the Department of Neurology, and the Department of Chemistry & Biochemistry have developed small molecule inhibitors of both the neutral sphingomyelinase 2 (nSMase2) and acetylcholinesterase (AChE) as novel therapeutics for neurodegenerative disorders caused by protein aggregation. BACKGROUND: Neurodegenerative diseases such...

Published: 2/14/2025 | Inventor(s): Varghese John, Neil Garg

Keywords(s): Cns, Therapeutics & Vaccines

Category(s): Therapeutics, Therapeutics > CNS and Neurology

1 2